Urinary Metabolomics in Newborns and Infants

Advances in Clinical Chemistry

Volumn 58, Issue , 2012, Pages 193-223

  Fanos, Vassilios ^a   Antonucci, Roberto ^b   Barberini, Luigi ^a   Atzori, Luigi ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Hospital Nostra Signora di Bonaria   (Italy)

Author keywords

Biomarkers; Infant; Metabolomics; Newborn; Nutrimetabolomics; Pharmametabolomics; Prediction; Urine

Indexed keywords

EID: 84862571524     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394383-5.00013-8     Document Type: Chapter

References (109)

1. Griffin J.L. Metabolic profiles to define the genome: can we hear the phenotypes?. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2004, 359:857-871.
2. Antonucci R., Atzori L., Barberini L., Fanos V. Metabolomics: the " new clinical chemistry" for personalized neonatal medicine. Minerva Pediatr. 2010, 62(S1):145-148.
3. Atzori L., Antonucci R., Barberini L., Griffin J.L., Fanos V. Metabolomics: a new tool for the neonatologist. J. Matern. Fetal Neonatal Med. 2009, 22(S3):50-53.
4. Dunn W.B., Broadhurst D.I., Atherton H.J., Goodacre R., Griffin J.L. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 2011, 40:387-426.
5. Bentley R. Secondary metabolite biosynthesis: the first century. Crit. Rev. Biotechnol. 1999, 19:1-40.
6. Wishart D.S., Knox C., Guo A.C., Eisner R., Young N., Gautam B., et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009, 37(Database issue):D603-D610.
7. Kind T., Fiehn O. Advances in structure elucidation of small molecules using mass spectrometry. Bioanal. Rev. 2010, 2:23-60.
8. Bothwell G.H., Griffin J.L. An introduction to biological nuclear magnetic resonance spectroscopy. Biol. Rev. Camb. Philos. Soc. 2010, [Epub ahead of print]. 10.1111/j.1469-185X.2010.00157.x.
9. Raamsdonk L.M., Teusink B., Broadhurst D., Zhang N., Hayes A., Walsh M.C., et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol. 2001, 19:45-50.
10. Nicholson J.K. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2006, 2:52. 10.1038/msb4100095.
11. Oliver S.G., Winson M.K., Kell D.B., Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998, 16:373-378.
12. Tweeddale H., Notley-McRobb L., Ferenci T. Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool (" metabolome" ) analysis. J. Bacteriol. 1998, 180:5109-5116.
13. Herrgard M.J., Swainston N., Dobson P., Dunn W.B., Arga K.Y., Arvas M., et al. A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology. Nat. Biotechnol. 2008, 26:1155-1160.
14. Wishart D.S. Current progress in computational metabolomics. Brief. Bioinform. 2007, 8:279-293.
15. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol. Biol. 2002, 48:155-171.
16. Nicholson J.K., Lindon J.C. Systems biology: metabonomics. Nature 2008, 455:1054-1056.
17. Preti G. Metabolomics comes of age?. The Scientist 2005, 19:8-12.
18. Horning E.C., Horning M.G. Metabolic profiles: gas-phase methods for analysis of metabolites. Clin. Chem. 1971, 17:802-809.
19. Pauling L., Robinson A.B., Teranishi R., Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl. Acad. Sci. U.S.A. 1971, 68:2374-2376.
20. Bales J.R., Higham D.P., Howe I., Nicholson J.K., Sadler P.J. Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin. Chem. 1984, 30:426-432.
21. Wishart D.S., Tzur D., Knox C., Eisner R., Guo A.C., Young N., et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007, 35(Database issue):D521-D526.
22. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
23. Blow N. Metabolomics: biochemistry's new look. Nature 2008, 455:697-700.
24. Lindon J.C., Keun H.C., Ebbels T.M., Pearce J.M., Holmes E., Nicholson J.K. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 2005, 6:691-699.
25. Dunn W.B., Bailey N.J., Johnson H.E. Measuring the metabolome: current analytical technologies. Analyst 2005, 130:606-625.
26. Ellis D.I., Dunn W.B., Griffin J.L., Allwood J.W., Goodacre R. Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 2007, 8:1243-1266.
27. Paintomics 2.0. (accessed February 2011). http://www.paintomics.org/cgi-bin/main2.cgi.
28. García-Alcalde F., García-López F., Dopazo J., Conesa A. Paintomics: a web based tool for the joint visualization of transcriptomics and metabolomics data. Bioinformatics 2011, 27:137-139.
29. Brereton R.G. Chemometrics for Pattern Recognition 2009, John Wiley & Sons Ltd., Chichester, United Kingdom, [1-509]. 10.1002/9780470746462.
30. Madsen R., Lundstedt T., Trygg J. Chemometrics in metabolomics-a review in human disease diagnosis. Anal. Chim. Acta 2010, 659:23-33.
31. Coen M., Holmes E., Lindon J.C., Nicholson J.K. NMR based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem. Res. Toxicol. 2008, 21:9-27.
32. Kaddurah-Daouk R., Kristal B.S., Weinshilboum R.M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 2008, 48:653-683.
33. Carraro S., Rezzi S., Reniero F., Héberger K., Giordano G., Zanconato S., et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am. J. Respir. Crit. Care Med. 2007, 175:986-990.
34. Edelstein C.L. Biomarkers in Kidney Disease 2011, Academic Press Elsevier, London.
35. Holmes E., Wilson I.D., Nicholson J.K. Metabolic phenotyping in health and disease. Cell 2008, 134:714-717.
36. Fell J.M., Thakkar H., Newman D.J., et al. Measurement of albumin and low molecular weight proteins in the urine of newborn infants using a cotton wool ball collection method. Acta Paediatr. 1997, 86:518-522.
37. Cuzzolin L., Mangiarotti P., Fanos V. Urinary PGE(2) concentrations measured by a new EIA method in infants with urinary tract infections or renal malformations. Prostaglandins Leukot. Essent. Fatty Acids 2001, 64:317-322.
38. Agostiniani R., Mariotti P., Cataldi L., Fanos V., Sani S., Zaccaron A., et al. Role of renal PGE2 in the adaptation from foetal to extrauterine life in term and preterm infants. Prostaglandins Leukot. Essent. Fatty Acids 2002, 67:373-377.
39. Ryan D., Robards K., Prenzler P.D., Kendall M. Recent and potential developments in the analysis of urine: a review. Anal. Chim. Acta 2011, 684:8-20.
40. Carraro S., Giordano G., Reniero F., Perilongo G., Baraldi E. Metabolomics a new frontier for research in pediatrics. J. Pediatr. 2009, 154:638-644.
41. Garrido-Gómez T., Dominguez F., Simón C. Proteomics of embryonic implantation. Handb. Exp. Pharmacol. 2010, 198:67-78.
42. Hill M., Pařízek A., Cibula D., Kancheva R., Jirásek J.E., Jirkovská M., et al. Steroid metabolome in fetal and maternal body fluids in human late pregnancy. J. Steroid Biochem. Mol. Biol. 2010, 122:114-132.
43. Hill M., Pařízek A., Kancheva R., Jirásek J.E. Reduced progesterone metabolites in human late pregnancy. Physiol. Res. 2010, 60:225-241.
44. Buhimschi C.S., Bhandari V., Hamar B.D., Bahtiyar M.O., Zhao G., Sfakianaki A.K., et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med. 2007, 4:e18.
45. Buhimschi I.A., Zhao G., Rosenberg V.A., Abdel-Razeq S., Thung S., Buhimschi C.S. Multidimensional proteomics analysis of amniotic fluid to provide insight into the mechanisms of idiopathic preterm birth. PLoS One 2008, 3:e2049.
46. Romero R., Mazaki-Tovi S., Vaisbuch E., Kusanovic J.P., Chaiworapongsa T., Gomez R., et al. Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J. Matern. Fetal Neonatal Med. 2010, 23:1344-1359.
47. Kenny L.C., Broadhurst D.I., Dunn W., Brown M., North R.A., McCowan L., et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 2010, 56:741-749.
48. Graca G., Duarte I.F., Barros A.S., Goodfellow B.J., Diaz S.O., Pinto J., et al. Impact of prenatal disorders on the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J. Proteome Res. 2010, 9:6016-6024.
49. Hyde M.J., Griffin J.L., Herrera E., Byrne C.D., Clarke L., Kemp P.R. Delivery by Caesarean section, rather than vaginal delivery, promotes hepatic steatosis in piglets. Clin. Sci. 2009, 118:47-59.
50. Shimizu Y.I., Sunaga E., Aoyagi S., Kanazawa K., Takahashi S., Takahashi Y., et al. Developmental delineation of metabolic-patterns of neonatal mice by using NMR-metabolic profiling on highly-diluted urine. J. Toxicol. Sci. 2009, 34:343-347.
51. Nissen P.M., Nebel C., Oksbjerg N., Bertram H.C. Metabolomics reveals relationship between plasma inositols and birth weight: possible markers for fetal programming of type 2 diabetes. J. Biomed. Biotechnol. 2011, [pii: 378268].
52. Antonucci R., Barberini L., Defraia R., Agostiniani R., Locci E., Cortesi P., et al. 1H NMR-based metabolomic analysis of urine from term and preterm neonates. J. Neonatal Perinatal Med. 2009, 2:216.
53. Atzori L., Antonucci R., Barberini L., Locci E., Marincola F.C., Scano P., et al. 1H NMR-based metabolomic analysis of urine from preterm and term neonates. Front. Biosci. 2011, E3:1005-1012.
54. Hyde M.J., Beckkonert O.P., Yap I.K.S., Booms C., Gale C.R.K., Logan K., et al. The effect of preterm delivery on the urinary metabolome, in: Summer Meeting 2010, The Neonatal Society, Nottingham UK. http://www.neonatalsociety.ac.uk.
55. Gu H., Pan Z., Xi B., Hainline B.E., Shanaiah N., Asiago V., et al. (1)H NMR metabolomics study of age profiling in children. NMR Biomed. 2009, 22:826-833.
56. Spitzer A.R., Chace D. Proteomics- and metabolomics-based neonatal diagnostics in assessing and managing the critically ill neonate. Clin. Perinatol. 2008, 35:695-716.
57. Aurora S., Snyder E.Y. Perinatal asphyxia. Manual of Neonatal Care 1997, 536-555. Lippincott, Williams & Wilkins, New York. fourth ed. J.P. Cloherty, R. Stark Ann (Eds.).
58. Solberg R., Enot D., Deigner H.P., Koal T., Scholl-Bürgi S., Saugstad O.D., et al. Metabolomic analyses of plasma reveals new insights into asphyxia and resuscitation in pigs. PLoS One 2010, 5:e9606.
59. Bruder E.D., Lee P.C., Raff H. Metabolomic analysis of adrenal lipids during hypoxia in the neonatal rat: implications in steroidogenesis. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E697-E703.
60. Wilkinson L., Chiu H., Rumballe B., Georgas K., JU A., Moritz K., et al. The effect of hypoxia on the development on the kidney 2010, P29.
61. Atzori L., Xanthos T., Barberini L., Antonucci R., Murgia F., Lussu M., et al. A metabolomic approach in an experimental model of hypoxia-reoxygenation in newborn piglets: urine predicts outcome. J. Matern. Fetal Neonatal Med. 2010, 23(S3):134-137.
62. Poulsen J.P., Oyasaeter S., Sanderud J., Rognum T.O., Saugstad O.D. Hypoxanthine, xanthine, and uric acid concentration in the cerebrospinal fluid, plasma and urine of hypoxemic pigs. Pediatr. Res. 1990, 28:477-481.
63. Seidl R., Stöckler-Ipsiroglu S., Rolinski B., Kohlhauser C., Herkner K.R., Lubec B., et al. Energy metabolism in graded perinatal asphyxia of the rat. Life Sci. 2000, 67:421-435.
64. Pallab B., Sabyasachi S., Nabendu C., Harendranath D. Correlation between Apgar Score and urinary uric acid to creatinine ratio in perinatal asphyxia. Indian J. Clin. Biochem. 2008, 23:361-364.
65. Banupriya C., Ratnakar P., Doureradjou N., Mondal N., Vishnu B., Koner B.C. Can urinary excretion rate of malondialdehyde, uric acid and protein predict the severity and impending death in perinatal asphyxia?. Clin. Biochem. 2008, 41:968-973.
66. Liu J., Wu J.Q., Yang J.J., Wei J.Y., Gao W.N., Guo C.J. Metabolomic study on vitamins B1, B2, and PP supplementation to improve serum metabolic profiles in mice under acute hypoxia based on 1H NMR analysis. Biomed. Environ. Sci. 2010, 23:312-318.
67. Chu C.Y., Xiao X., Zhou X.G., Lau T.K., Rogers M.S., Fok T.F., et al. Metabolomic and bioinformatic analyses in asphyxiated neonates. Clin. Biochem. 2006, 39:203-209.
68. Vinayavekhin N., Homan E.A., Saghatelian A. Exploring disease through metabolomics. ACS Chem. Biol. 2010, 15:91-103.
69. Wikoff W., Gangoiti J., Barshop B., Siuzdak G. Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin. Chem. 2007, 53:2169-2176.
70. German J.B., Roberts M.A., Fay L., Watkins S.M. Metabolomics and individual metabolic assessment: the next great challenge for nutrition. J. Nutr. 2002, 132:2486-2487.
71. van Ommen B., Bouwman J., Dragsted L.O., Drevon C.A., Elliott R., de Groot P., et al. Challenges of molecular nutrition research 6: the nutritional phenotype database to store, share and evaluate nutritional systems biology studies. Genes Nutr. 2010, 5:189-203.
72. Wishart D.S. Application of metabolomics in drug discovery and development. Drugs R&D 2008, 9:307-322.
73. Walsh M.C., Brennan L., Malthouse J.P.G., Roche H.M., Gibney M.I. Effect of the acute standardization on the urinary, plasma and salivary metabolic profiles of healthy humans. Am. J. Clin. Nutr. 2006, 84:531-539.
74. O'Sullivan A., Gibney M.J., Brennan L. Dietary intake patterns are reflected in metabolomic profiles: potential role in dietary assessment studies. Am. J. Clin. Nutr. 2011, 93:314-321.
75. Suhre K., Meisinger C., Döring A., Altmaier E., Belcredi P., Gieger C., et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One 2010, 5:e13953.
76. Malandrino N., Smith R.J. Personalized medicine in diabetes. Clin. Chem. 2011, 57:231-240.
77. Shen Q., Xu H., Wei L.M., Chen J., Liu H.M. Intrauterine growth restriction and postnatal high-protein diet affect the kidneys in adult rats. Nutrition 2011, 27:364-371.
78. Chen J., Xu H., Shen Q., Guo W., Sun L. Effect of postnatal high-protein diet on kidney function of rats exposed to intrauterine protein restriction. Pediatr. Res. 2010, 68:100-104.
79. Modi N., Hyde M.J., Parkinson J., Yap I.K.S., Beckonert O.P., Holmes E. Deciphering the metabolic pathways perturbed by preterm birth. J. Neonatal Perinatal Med. 2010, 3:254.
80. Reali A., Greco F., Fanaro S., Atzei A., Puddu M., Moi M., et al. Fortification of maternal milk for very low birth weight (VLBW) pre-term neonates. Early Hum. Dev. 2010, 86(S1):33-36.
81. Clark R.H., Chace D.H., Spitzer A.R. The effects of two different doses of amino acid administrations on growth and blood amino acids in premature neonates admitted to the NICU: a randomized controlled trial. Pediatrics 2007, 120:1286-1296.
82. Decramer S., Wittke S., Mischak H., Zürbig P., Walden M., Bouissou F., et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med. 2006, 12:398-400.
83. Drube J., Zürbig P., Schiffer E., Lau E., Ure B., Glüer S., et al. Urinary proteome analysis identifies infants but not older requiring pyelopasty. Pediatr. Nephrol. 2010, 25:1673-1678.
84. Atzori L., Antonucci R., Barberini L., Locci E., Cesare Marincola F., Scano P., et al. 1H NMR-based metabolic profiling of urine from children with nephrouropathies. Front. Biosci. 2010, E2:725-732.
85. Mesrobian H.G. Urinary proteome analysis and the management of ureteropelvic junction obstruction. Pediatr. Nephrol. 2010, 25:1595-1596.
86. Stewart J.D., Bolt H.M. Metabolomics: biomarkers of disease and drug toxicity. Arch. Toxicol. 2011, 85:3-4.
87. Boudonck K.J., Rose D.J., Karoly E.D., Lee D.P., Lawton K.A., Lapinskas P.J. Metabolomics for early detection of drug-induced kidney injury: review of the current status. Bioanalysis 2009, 1:1645-1663.
88. Christians U., Schmitz V., Schöning W., Bendrick-Peart J., Klawitter J., Haschke M., et al. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality and challenges. Ther. Drug Monit. 2008, 30:151-158.
89. Kim C.D., Kim E.Y., Yoo H., Lee J.W., Ryu do H., Noh D.W., et al. Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. Transplantation 2010, 90:748-756.
90. Espandiari P., Zhang J., Rosenzweig B.A., Vaidya S.V., Sun J., et al. The utility of a Rodent Model in detecting pediatric drug-induced nephrotoxicity. Toxicol. Sci. 2007, 99:637-648.
91. Lv H., Liu L., Song T., Lu J., Chen X. Ingenuity pathways analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs. Mol. Biosyst. 2010, 6:2056-2067.
92. Ellinger-Ziegelbauer H., Adler M., Amberg A., Brandenburg A., Callanan J.J., Connor S., et al. The enhanced value of combining conventional and " omics" analyses in early assessment of drug-induced hepatobiliary injury. Toxicol. Appl. Pharmacol. 2011, 252:97-111.
93. Bando K., Kunimatsu T., Sakai J., Kimura J., Funabashi H., Seki T., et al. GC-MS-based metabolomics reveals mechanism of action for hydrazine induced hepatotoxicity in rats. J. Appl. Toxicol. 2010, [Epub ahead of print]. 10.1002/jat.1591.
94. O'Connell T.M., Watkins P.B. The application of metabonomics to predict drug-induced liver injury. Clin. Pharmacol. Ther. 2010, 88:394-399.
95. Lewis G.D., Asnani A., Gerszten R.E. Application of metabolomics to cardiovascular biomarker and pathway discovery. J. Am. Coll. Cardiol. 2008, 52:117-123.
96. Alexander D., Lombardi R., Rodriguez G., Mitchell M.M., Marian A.J. Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur. J. Clin. Invest. 2011, 41:527-538.
97. Beger R., Holland R., Sun J., Schnackenberg L., Moore P., Dent C., et al. Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr. Nephrol. 2008, 23:977-984.
98. Razeghi P., Young M.E., Alcorn J.L., Moravec C.S., Taegtmeyer F.H. Metabolic gene expression in fetal and failing human heart. Circulation 2001, 104:2923-2931.
99. Atzori L., Barberini L., Lussu M., Murgia F., Noto A., Mercuro G., et al. Metabolomics & Patent Ductus Arteriosus diagnosis: Is 1H-NMR (nuclear magnetic resonance) spectroscopy of urine at birth predictive as ultrasound?. J. Matern. Fetal Neonatal Med. 2011, 24(S). I (abstract).
100. Saude E.J., Obiefuna I.P., Somorjai R.L., Ajamian F., Skappak C., Ahmad T., et al. Metabolomic biomarkers in a model of asthma exacerbation: urine nuclear magnetic resonance. Am. J. Respir. Crit. Care Med. 2009, 179:25-34.
101. Slupsky C.M. NMR-based analysis of metabolites in urine provides rapid diagnosis and etiology of pneumonia. Biomark. Med. 2010, 4:195-197.
102. Laiakis E.C., Morris G.A., Fornace A.J., Howie S.R. Metabolomic analysis in severe childhood pneumonia in the Gambia, West Africa: findings from a pilot study. PLoS One 2010, 5:e12655.
103. Kaminsky D.A., Irvin C.G., Sterk P.J. Complex systems in pulmonary medicine: a systems biology approach to lung disease. J. Appl. Physiol. 2011, 110:1716-1722.
104. Lacy P. Metabolomics of sepsis-induced acute lung injury: a new approach for biomarkers. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300:L1-L3.
105. Cantor G.H. Metabolomics and mechanisms: sometimes the fisher catches a big fish. Toxicol. Sci. 2010, 118:321-323.
106. Fanos V., Antonucci R., Barberini L., Noto A., Atzori L. Clinical application of metabolomics in neonatology. J. Matern. Fetal. Neonatal. Med. 2012, 25S1:104-109.
107. Fanos V., Atzori L., Dessì A., D'Aloja E., Finco G., Faa G. The kidney in post-asphyctic syndrome: state of the art. Developmental Nephrology: from Embryology to Metabolomics 2011, 159-179. Hygeia Press, Caglliari, Italy. V. Fanos, R.L. Chevalier, G. Faa, L. Cataldi (Eds.).
108. Fanos V., Barberini L., Antonucci R., Atzori L. Metabolomics in neonatology and pediatrics. Clin. Biochem. 2011, 44:452-454.
109. Fanos V., Barberini L., Antonucci R., Atzori L. Pharma-metabolomics in Neonatology: is it a Dream or a Fact?. Curr. Pharm. Des. 2012 Feb 27., (S). [Epub ahead of print].